ORIC PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $33.2M | $28.8M | $25.6M | $25.1M | $22.0M | $13.4M | $5.7M |
| Operating Income | — | $-143.0M | $-142.9M | $-110.8M | $-91.8M | $-78.9M | $-74.2M | $-28.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-129.5M | $-127.8M | $-100.7M | $-89.1M | $-78.7M | $-73.7M | $-26.9M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 | $-3.36 | $-14.15 |
| EPS (Diluted) | — | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 | $-3.36 | $-14.15 |
| Shares Outstanding (Basic) | 100.4M | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 36.7M | 2.0M |
| Shares Outstanding (Diluted) | 100.4M | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 36.7M | 2.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |
Those who do not remember the past are condemned to repeat it.